I specialize in biotech and healthcare investment analysis, integrating clinical expertise with a solid foundation in business strategy. My approach leverages detailed risk-return charts and DCF analyses to clearly communicate the investment potential and associated risks. I advocate for a barbell portfolio strategy, with 90% allocated to secure assets such as Treasuries and broad-market ETFs, and 10% to high-alpha stocks. This balanced approach ensures that all recommendations are made within a context of ...

ADHERE was largest and most innovative clinical trial of CIDP patients to date VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) demonstrated reduction in disease progression, reduced risk of relapse and rapid onset of action VYVGART Hytrulo is first and only neonatal Fc receptor (FcRn) blocker FDA-approved to treat CIDP September 19, 2024 – 7:00 am CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people sufferi ...

argenex SE (ARGX) shares rallied 4% in the last trading session to close at $548.49. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 6.1% gain over the past four weeks.The stock rallied as optimism grew over the company’s marketed product, Vyvgart Hytrulo (efgartigimod), which is approved for treating adult patients with generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has argenex SE (ARGX) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.argenex SE is a member of the Medical sector. This group includes 1019 individual stocks and currently holds a Zacks Sector Rank of #3. The Zacks Sector Rank gauges the strength ...

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, July 31:argenx SE (ARGX) : This biotechnology company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 56.2% over the last 60 days.argenx's shares gained 32.9% over the last three months compared with the S&P 500’s advanced of 8.4%. The company possesses a Momentum Score of A.Vizsla Silver Corp. (VZLA) : This mineral exploration company has a Zacks R ...

argenex SE (ARGX) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.The power of a cha ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. argenex SE (ARGX) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.argenex SE is a member of the Medical sector. This group includes 1024 individual stocks and currently holds a Zacks Sector Rank of #4. The Zac ...

argenx SE (NASDAQ:ARGX) Q2 2024 Earnings Conference Call July 25, 2024 8:30 AM ET Company Participants Beth DelGiacco - Vice President, Global Head of Corporate Communications & Investor Relations Tim Van Hauwermeiren - Chief Executive Officer Karl Gubitz - Chief Financial Officer Karen Massey - Chief Operating Officer Conference Call Participants James Gordon - JPMorgan Tazeen Ahmad - Bank of America Allison Bratzel - Piper Sandler Rajan Sharma - Goldman Sachs Derek Archila - Wells Fargo Akash Tewari - Jef ...

| --- | --- | --- | --- | --- | --- | --- | |-------|---------|-------|----------------------------------------------------|----------------------------|-------|-------| | | | | | | | | | | | | | | | | | Q 2 | 202 4 | | Reaching Patients through E A R N I N G S C A L L | \| J u l y 2 5 , 2 0 2 4 | | | | | | | Immunology Innovation | | | | | | | | | | | | Forward Looking Statements 2 This presentation has been prepared by argenx se ("argenx" or the "company") for informational purposes only and not for any o ...

Core Insights - argenx SE reported global net product sales of $478 million in the second quarter of 2024, a significant increase from $269 million in the same period of 2023 [6][13] - The company launched VYVGART Hytrulo for chronic inflammatory demyelinating polyneuropathy (CIDP) in the U.S. following FDA approval on June 21, 2024 [5][6] - argenx aims to achieve its Vision 2030 goals, which include treating 50,000 patients globally and obtaining 10 labeled indications across its approved assets [4][22] Financial Performance - Total operating income for the second quarter of 2024 was $489 million, compared to $281 million in the same period of 2023 [11][13] - Research and development expenses increased to $225 million in Q2 2024 from $196 million in Q2 2023, reflecting ongoing investment in clinical development [12][13] - The company reported a profit of $29 million for the second quarter of 2024, a turnaround from a loss of $94 million in the same period of 2023 [16] Product Development and Pipeline - argenx is on track to initiate four additional registrational studies for efgartigimod and empasiprubart by the end of 2024 [3][22] - The company is advancing its pipeline with multiple candidates, including efgartigimod in 15 indications and empasiprubart for various autoimmune diseases [8][9] - A registrational study for VYVGART in ocular myasthenia gravis is expected to start by the end of 2024 [6][9] Regulatory Approvals and Market Expansion - VYVGART SC received approval for generalized myasthenia gravis (gMG) in China, with additional regulatory decisions expected in Switzerland, Australia, and Saudi Arabia in 2024 [6][13] - The company plans to file for regulatory approval of VYVGART SC in Canada by the end of 2024 [6][9] - Ongoing regulatory submissions for CIDP are under review in China, Japan, and Europe, with decisions anticipated in 2025 [6][9] Strategic Vision - The Vision 2030 plan includes a commitment to innovation in autoimmune disease treatment and aims to solidify argenx's leadership in FcRn biology [4][22] - The company is focused on expanding its patient reach and enhancing its product offerings through label expansions and new formulations [3][4] - argenx is investing in its Immunology Innovation Program to support the development of five new molecules in Phase 3 by 2030 [10][22]